CDER Product-Specific Guidances Withdrawn Listing

Updated November 19th, 2024

Active Ingredient	Type of Guidance	Route and Dosage Form	RLD	Date PSG posted, or revised	FEDERAL REGISTER Notice Date
Butenafine Hydrochloride	Draft	Topical Cream	021408	03/01/2012	02/01/2015
Hydroxyprogesterone Caproate	Draft	Subcutaneous Solution	021945	09/16/2019	04/06/2023
Lorcaserin Hydrochloride	Draft	Oral Tablet, Extended Release	022529	03/01/2015	03/04/2021
Lorcaserin Hydrochloride	Draft	Oral Tablet, Extended Release	208524	05/01/2017	03/04/2021
Lovastatin; Niacin	Draft	Oral Tablet, Extended Release	021249	07/01/2009	04/18/2016
Melphalan Flufenamide Hydrochloride	Draft	Intravenous Powder	214383	11/17/2022	04/18/2024
Mobocertinib Succinate	Draft	Oral Capsule	215310	08/21/2023	07/15/2024
Niacin; Simvastatin	Draft	Oral Tablet, Extended Release	022078	10/01/2011	04/18/2016
Oxymorphone Hydrochloride	Draft	Oral Tablet, Extended Release	201655	10/04/2016	12/23/2020